Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.
Publication
, Journal Article
Schulman, KA; Balu, S; Reed, SD
Published in: N Engl J Med
October 22, 2015
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
October 22, 2015
Volume
373
Issue
17
Start / End Page
1591 / 1593
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Serine Endopeptidases
- Proprotein Convertases
- Proprotein Convertase 9
- Insurance, Health
- Insurance
- Hyperlipidemias
- Humans
- General & Internal Medicine
Citation
APA
Chicago
ICMJE
MLA
NLM
Schulman, K. A., Balu, S., & Reed, S. D. (2015). Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums. N Engl J Med, 373(17), 1591–1593. https://doi.org/10.1056/NEJMp1509863
Schulman, Kevin A., Suresh Balu, and Shelby D. Reed. “Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.” N Engl J Med 373, no. 17 (October 22, 2015): 1591–93. https://doi.org/10.1056/NEJMp1509863.
Schulman KA, Balu S, Reed SD. Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums. N Engl J Med. 2015 Oct 22;373(17):1591–3.
Schulman, Kevin A., et al. “Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.” N Engl J Med, vol. 373, no. 17, Oct. 2015, pp. 1591–93. Pubmed, doi:10.1056/NEJMp1509863.
Schulman KA, Balu S, Reed SD. Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums. N Engl J Med. 2015 Oct 22;373(17):1591–1593.
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
October 22, 2015
Volume
373
Issue
17
Start / End Page
1591 / 1593
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Serine Endopeptidases
- Proprotein Convertases
- Proprotein Convertase 9
- Insurance, Health
- Insurance
- Hyperlipidemias
- Humans
- General & Internal Medicine